Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review

Aquaporin A/S (AQP.CO) has significantly lowered its revenue guidance for the financial year ending December 31, 2025, from a prior outlook of DKK 60-80 million to a revised range of DKK 40-50 million, attributing the cut to lower order inflow and delayed orders. Concurrently, the company has initiated a strategic review to explore various capital raising opportunities, including equity or debt financing and/or strategic transactions or partnerships, while its EBITDA loss guidance of DKK 45-55 million remains unchanged.

Analysis

Aquaporin A/S has issued a significant negative revision to its FY2025 revenue outlook, cutting the guidance from a range of 60-80 million Danish Kroner to 40-50 million Kroner. Management attributes this substantial downgrade to a lower-than-expected inflow of new orders and delays in existing ones, indicating a sharp deterioration in its commercial pipeline or execution capabilities. Concurrently, the company has initiated a strategic review to secure additional capital through options including equity or debt financing, or a strategic transaction, signaling potential liquidity pressures stemming from its operational challenges. Notably, while revenue expectations have been slashed, the guidance for an EBITDA loss (before special items) remains unchanged at 45-55 million Kroner, suggesting that either the projected revenue shortfall is from low-margin streams or that the company is implementing aggressive cost controls to preserve cash. Further clarity on this dynamic will be a key focus for the Half-Year Interim Report on August 21, 2025.

Key Decisions for Investors

• Given the severe revenue guidance cut and the concurrent search for capital, investors should adopt a highly cautious stance as this combination points to significant operational and financial distress.
• The unchanged EBITDA loss guidance, despite a ~33% reduction in the revenue midpoint, is a critical data point; investors should scrutinize the upcoming August 21 report for details on cost management and margin structure.
• The strategic review introduces significant binary risk; a dilutive equity financing could exert further downward pressure on the stock, while a strategic partnership or transaction could serve as a positive catalyst, making its outcome a key factor to monitor.